Press Release Archive
Press Releases
January 2022
01.03.2022 Covid-19 Vaccines Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
December 2021
12.30.2021 Finance Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference 12.28.2021 Finance Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts 12.23.2021 Covid-19 Vaccines Pfizer and BioNTech Submit Updated Longer-Term Follow-Up Data of COMIRNATY® in Adolescents 12 Through 15 Years of Age to EMA 12.22.2021 Covid-19 Medicines Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment 12.22.2021 Covid-19 Medicines Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19 12.20.2021 Medicines Research Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate 12.20.2021 Covid-19 Vaccines Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply 12.17.2021 Covid-19 Research Vaccines Pfizer and BioNTech Provide Update on Ongoing Studies of COVID-19 Vaccine 12.17.2021 Medicines EMA Adopts a Positive CHMP Opinion for Pfizer’s and OPKO’s Somatrogon, a Long-Acting Treatment for Pediatric Growth Hormone Deficiency 12.17.2021 Vaccines CHMP Issues Positive Opinion for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Vaccine-Type Pneumococcal Pneumonia in Adults 12.17.2021 Medicines Pfizer Receives Positive CHMP Opinion for LORVIQUA® (lorlatinib) as First-Line Treatment for ALK-Positive Advanced Lung Cancer
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.